On February 28, 2020 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense reported that Kineta’s management team has been invited to participate at the Opal Group’s Family Office Winter Forum in New York, New York on March 2, 2020 (Press release, Kineta, FEB 28, 2020, View Source;utm_medium=rss&utm_campaign=kineta-invited-to-participate-at-the-opal-groups-winter-forum [SID1234554983]). Craig W. Philips, Kineta President, will participate in a panel discussion regarding the Impact of Developing Disruptive Technologies. His talk will center on the development of innovative new drug treatments for cancer patients, especially in those areas of high unmet medical need. Mr. Philips will be presenting at 3:00 PM EST on Tuesday March 3 at the New York Athletic Club.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!